GSK defeats Novadart trade mark for generic rival to prostate drug Avodart

Intellectual Property 2024-08-12 11:47 pm By Andy Sidler | Melbourne

A GlaxoSmithKline unit has defeated Nova Pharmaceuticals’ bid to trade mark ‘Novadart’ for a generic version of the British company’s market-leading drug prostate drug ‘Avodart’, with a delegate finding the mark would cause consumer confusion.